尼妥珠单抗联合IMRT治疗老年局部晚期食管癌患者的疗效观察

The efficacy and safety of nimotuzumab combined with IMRT in locally advanced esophageal carcinoma of elderly patients

目的:探讨尼妥珠单抗联合适型调强放射治疗(IMRT)在局部晚期老年食管癌患者中的疗效和安全性。方法:67例老年局部晚期食管癌患者随机分为试验组和对照组,试验组34例予尼妥珠单抗联合IMRT治疗,对照组33例只行IMRT治疗。结果:试验组与对照组的近期有效率(RR)分别为85.2%和63.6%,疾病控制率(DCR)分别为97.1%和81.8%,差异均有统计学意义(P<0.05);1、2、3年生存率虽然试验组较对照组有提高,但差异无统计学意义(P>0.05);2组不良反应相似,差异无统计学意义(P>0.05)。结论:尼妥珠单抗联合IMRT可以明显提高局部晚期老年食管癌患者的RR和DCR,但未明显提高患者的1、2、3年生存率。

Objective:To evaluate the efficacy and safety of nimotuzumab combined with concurrent intensity-modulated radiotherapy(IMRT)for elderly patients with locally advanced esophageal carcinoma.Methods:Sixty-seven elderly patients with esophageal carcinoma randomly divided into the experimental group(34 patients)and the control group(33 patients).Thirty-four patients of the trial group received nimotuzumab combined with IMRT.Thirty-three patients of the control group received only IMRT.Results:The resent response rate(RR)of the experimental group and control group were 85.2%and 63.6%,and the disease control rate(DCR)were 97.1%and 81.8%,respectively(P<0.05).The 1-,2-,3-survival rate of the experimental group were improved to some degree,but the result don’t have difference(P>0.05).The adverse effects of the two group had similarity(P>0.05).Conclusion:Nimotuzumab combined with IMRT could increase RR and DCR in the elderly patients with locally advance esophageal carcinoma,but it couldn’t significantly improve the 1-,2-,3-survival rate.